Advertisement

Clinical Rheumatology

, Volume 38, Issue 11, pp 3033–3039 | Cite as

Predictors and the optimal duration of sustained remission in rheumatoid arthritis

  • Sibel Yilmaz-OnerEmail author
  • Ummugulsum Gazel
  • Meryem Can
  • Pamir Atagunduz
  • Haner Direskeneli
  • Nevsun Inanc
Original Article
  • 99 Downloads

Abstract

Objective

To determine predictors and optimal duration of sustained remission (SR) in patients with rheumatoid arthritis (RA).

Methods

A total of 428 consecutive patients with RA visiting our clinic routinely between 2012 and 2013 were evaluated. Seventy seven of these patients in DAS28 remission were enrolled and followed up for 62.2 ± 9.9 months. Patients in remission ≥ 6 months (SR) and shorter (non: N-SR) were compared in terms of demographic-clinical data and the psychosocial factors. At enrollment, 1st and 5th years, patients in DAS28, SDAI, and Boolean remission were determined.

Results

Sixty three patients were in SR and 14 in N-SR. Lower baseline DAS28 and HAQ scores, anti-CCP were positive predictors of SR. Although the presence of anxiety, depression, fibromyalgia, and fatigue were lower in the SR group, there was no significance. Patients in DAS28 remission (100%) at baseline reduced to 64% at 1st and 42.6% at 5th years. Patients satisfying SDAI and Boolean remission at these three visits were 49%, 44%, and 32.4% vs 41%, 28%, and 20.6%, respectively. If the duration of remission is defined as 6 months, the remission rates of SDAI at inclusion and fifth years’ visits were similar but Boolean remission rates differed significantly and if it is accepted as ≥ 12 months, both the SDAI and Boolean remission rates were not different.

Conclusion

Low DAS28 and HAQ scores at baseline, anti-CCP were positive predictors of SR. Instead of 6 months, remission duration for ≥ 12 months would probably help us to predict SR independently from the chosen criteria; Boolean or SDAI.

Keywords

ACR/EULAR definition of remission Disease activity score Predictors Rheumatoid arthritis SDAI Sustained remission 

Notes

Compliance with ethical standards

Written informed consent was obtained from all patients and the study was approved by the Marmara University School of Medicine Ethics Committee for Clinical and Laboratory Research (the approval number was 09.2012.0208).

Disclosures

None.

References

  1. 1.
    Yelin E, Trupin L, Wong B, Rush S (2002) The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 29:1851–1857PubMedGoogle Scholar
  2. 2.
    Pollard L, Choy EH, Scott DL (2005) The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol 23:43–52Google Scholar
  3. 3.
    Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3–15CrossRefGoogle Scholar
  4. 4.
    Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977CrossRefPubMedGoogle Scholar
  5. 5.
    Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS (2009) Rheumatoid arthritis joint progression in sustained remission is determined by disease activitylevels preceding the period of radiographic assessment. Arthritis Rheum 60:1242–1249CrossRefPubMedGoogle Scholar
  6. 6.
    Einarsson JT, Geborek P, Saxne T, Kristensen LE, Kapetanovic MC (2016) Sustained remission improves physical function in patients with established rheumatoid arthritis, and should be a treatment goal: a prospective observational cohort study from southern Sweden. J Rheumatol 43:1017–1023CrossRefPubMedGoogle Scholar
  7. 7.
    Radner H, Alasti F, Smolen JS, Aletaha D (2015) Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. Arthritis Res Ther 17:203CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Batko B, Urbański K, Świerkot J, Wiland P, Raciborski F, Jędrzejewski M, Koziej M, Cześnikiewicz-Guzik M, Guzik TJ, Stajszczyk M (2019) Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis. Clin Rheumatol.  https://doi.org/10.1007/s10067-019-04579-1
  9. 9.
    Iannone F, Salaffi F, Fornaro M, di Carlo M, Gentileschi S, Cantarini L, Lopalco G (2018) Influence of baseline modified rheumatic disease comorbidity index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis in real-world settings. Eur J Clin Investig 48(11):e13013.  https://doi.org/10.1111/eci.13013 CrossRefGoogle Scholar
  10. 10.
    Khan NA, Spencer HJ, Abda E, Aggarwal A, Alten R, Ancuta C, Andersone D, Bergman M, Craig-Muller J, Detert J, Georgescu L, Gossec L, Hamoud H, Jacobs JWG, Laurindo IMM, Majdan M, Naranjo A, Pandya S, Pohl C, Schett G, Selim ZI, Toloza S, Yamanaka H, Sokka T (2012) Determinants of discordance in patients’ and physicians’ rating of rheumatoid arthritis disease activity. Arthritis Care Res 64:206–214CrossRefGoogle Scholar
  11. 11.
    Masri KR, Shaver TS, Shahouri SH et al (2012) Validity and reliability problems with patient global as a component of the ACR/EULAR remission criteria as used in clinical practice. J Rheumatol 39:1139–1145CrossRefPubMedGoogle Scholar
  12. 12.
    Studenic P, Smolen JS, Aletaha D (2012) Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis 71:1702–1705CrossRefPubMedGoogle Scholar
  13. 13.
    Inanc N, Yilmaz-Oner S, Can M, Sokka T, Direskeneli H (2014) The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis. J Rheumatol 41:1755–1760CrossRefPubMedGoogle Scholar
  14. 14.
    Radner H, Yoshida K, Tedeschi S, Studenic P, Frits M, Iannaccone C, Shadick NA, Weinblatt M, Aletaha D, Smolen JS, Solomon DH (2017) Different rating of global rheumatoid arthritis disease activity in rheumatoid arthritis patients with multiple morbidities. Arthritis Rheum 69:720–727CrossRefGoogle Scholar
  15. 15.
    Ajeganova S, van Steenbergen HW, van Nies JA, Burgers LE, Huizinga TW, van der Helm-van Mil AH (2016) Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Ann Rheum Dis 75:867–873CrossRefPubMedGoogle Scholar
  16. 16.
    Nagy G, van Vollenhoven RF (2015) Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? Arthritis Res Ther 17:181CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C (2010) Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res 62:1128–1143CrossRefGoogle Scholar
  18. 18.
    Sung YK, Yoshida K, Prince FHM et al (2019) Prevalence and predictors for sustained remission in rheumatoid arthritis. PLoS One 14(4):e0214981.  https://doi.org/10.1371/journal.pone.0214981 eCollection 2019CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Einarsson JT, Willim M, Ernestam S, Saxne T, Geborek P, Kapetanovic MC (2019) Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a nationwide study in Sweden. Rheumatology (Oxford) 58:227–236CrossRefGoogle Scholar
  20. 20.
    Hamann PDH, Pauling JD, McHugh N, Shaddick G, Hyrich K; BSRBR-RA Contributors Group (2019) Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. Rheumatology (Oxford) pii: kez188.  https://doi.org/10.1093/rheumatology/kez188
  21. 21.
    Valor L, Garrido J, Martínez-Estupiñán L, Hernández-Flórez D, Janta I, López-Longo FJ, Monteagudo I, González CM, Naredo E (2018) Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugs. Rheumatol Int 38:1465–1470CrossRefPubMedGoogle Scholar
  22. 22.
    Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMedGoogle Scholar
  23. 23.
    Ramey DR, Raynauld JP, Fries JF (1992) The health assessment questionnaire 1992: status and review. Arthritis Care Res 5:119–129CrossRefPubMedGoogle Scholar
  24. 24.
    Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370CrossRefGoogle Scholar
  25. 25.
    Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB (2010) The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 62:600–610CrossRefGoogle Scholar
  26. 26.
    Belza BL (1995) Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 22:639–643PubMedGoogle Scholar
  27. 27.
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48CrossRefGoogle Scholar
  28. 28.
    Fransen J, Creemers MC, Van Riel PL (2004) Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43:1252–1255CrossRefGoogle Scholar
  29. 29.
    Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42:244–257CrossRefGoogle Scholar
  30. 30.
    Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M (2011) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404–413CrossRefPubMedGoogle Scholar
  31. 31.
    Schipper LG, Fransen J, den Broeder AA, Van Riel PL (2010) Time to achieve remission determines time to be in remission. Arthritis Res Ther 12:R97CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Hamann P, Holland R, Hyrich K, Pauling JD, Shaddick G, Nightingale A, McHugh N (2017) Factors associated with sustained remission in rheumatoid arthritis in patients treated with anti-tumor necrosis factor. Arthritis Care Res 69:783–793CrossRefGoogle Scholar
  33. 33.
    Einarsson JT, Geborek P, Saxne T, Kapetanovic MC (2015) Sustained remission in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis: a population-based cohort study. J Rheumatol 42:741–748CrossRefPubMedGoogle Scholar
  34. 34.
    Castrejón I, Dougados M, Combe B, Fautrel B, Guillemin F, Pincus T (2016) Prediction of remission in a French early arthritis cohort by RAPID3 and other core data set measures, but not by the absence of rheumatoid factor, anticitrullinated protein antibodies, or radiographic erosions. J Rheumatol 43:1285–1291CrossRefPubMedGoogle Scholar
  35. 35.
    Martire MV, Marino Claverie L, Duarte V, Secco A, Mammani M (2015) Factors associated with sustained remission in patients with rheumatoid arthritis. Reumatol Clin 11:237–241CrossRefPubMedGoogle Scholar
  36. 36.
    Haschka J, Englbrecht M, Hueber AJ, Manger B, Kleyer A, Reiser M, Finzel S, Tony HP, Kleinert S, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Wendler J, Schuch F, Ronneberger M, Lorenz HM, Nuesslein H, Alten R, Demary W, Henes J, Schett G, Rech J (2016) Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 75:45–51CrossRefPubMedGoogle Scholar
  37. 37.
    Wevers-de Boer KV, Heimans L, Visser K et al (2015) Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment. Rheumatology (Oxford) 54:1380–1384CrossRefGoogle Scholar
  38. 38.
    Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D (2010) Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res 62:857–864CrossRefGoogle Scholar
  39. 39.
    Katz PP, Yelin EH (1993) Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J Rheumatol 20:790–796PubMedGoogle Scholar
  40. 40.
    Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, Pedersen R, Robertson D, Freundlich B, Sato R (2010) Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis 69:222–225CrossRefPubMedGoogle Scholar
  41. 41.
    Ranzolin A, Brenol JC, Bredemeier M et al (2009) Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum 61:794–800CrossRefPubMedGoogle Scholar
  42. 42.
    Rech J, Hueber AJ, Finzel S, Englbrecht M, Haschka J, Manger B, Kleyer A, Reiser M, Cobra JF, Figueiredo C, Tony HP, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Henes J, Krueger K, Schett G (2016) Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis 75:1637–1644CrossRefPubMedGoogle Scholar
  43. 43.
    Yilmaz-Oner S, Ozen G, Can M, Atagunduz P, Direskeneli H, Inanc N (2015) Biomarkers in remission according to different criteria in patients with rheumatoid arthritis. J Rheumatol 42:2066–2070CrossRefPubMedGoogle Scholar
  44. 44.
    Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A (2011) Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford) 50:401–409CrossRefGoogle Scholar
  45. 45.
    Lillegraven S, Prince FH, Shadick NA et al (2012) Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis 71:681–686CrossRefPubMedGoogle Scholar
  46. 46.
    Ajeganova S, Huizinga T (2017) Sustained remission in rheumatoid arthritis:latest evidence and clinical considerations. Ther Adv Musculoskelet Dis 9:249–262CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Prince FH, Bykerk VP, Shadick NA et al (2012) Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther 14:R68CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  1. 1.Medical Faculty, Department of RheumatologyMarmara UniversityIstanbulTurkey

Personalised recommendations